Delivery Order SPE2DB22D3004-SPE2DB25FRU94
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,334.85 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,739.99 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count package) on August 5, 2025, with completion targeted for August 6, 2025. This contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive procurement. The award represents a child delivery order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $12,789.51 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units). This firm fixed-price delivery order, issued on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a non-competitive set-aside contract. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count units) under a firm fixed-price contract valued at $1,076.10. This non-set-aside award is part of a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion vehicle running through December 2026 that serves as the primary global pharmaceutical support mechanism for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count) with a ceiling value of $1,512.73. This firm fixed-price delivery order, which is non-set-aside and competitively awarded, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. The delivery order falls under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $2,113.94 delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120 count) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a $5,414.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count units). This is a non-set-aside, competitively awarded contract with an ultimate completion date of July 31, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120 count) on July 31, 2025, with a ceiling value of $1,422.22 and an ultimate completion date of August 1, 2025. This non-set-aside, firm fixed-price delivery order was competitively awarded and represents a continuation of the company's role as a critical pharmaceutical supplier to federal medical procurement needs. The place of performance is located in...
- The Defense Logistics Agency awarded a $17,412.86 delivery order to AmerisourceBergen Drug Corp for 180 tablets of Mesalamine 800 mg delayed-release medication, with an ultimate completion date of July 29, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120 count) with a ceiling value of $1,914.97. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award to this qualified pharmaceutical distributor. The order is set to be completed by July 31, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FRU94Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,489.23 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120 count) under a firm fixed price arrangement. The contract, which was competitively awarded with no set-aside designation, is scheduled for completion by August 5, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion prime vendor agreement running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement through the DLA's Medical Supply Chain. The company leverages its comprehensive prime vendor agreement to supply a wide range of pharmaceutical products, medical devices, and specialized healthcare commodities to support military healthcare programs and other federal healthcare systems worldwide. This particular delivery order for Mesalamine—a medication commonly used in the treatment of inflammatory bowel conditions—exemplifies the company's ongoing role in fulfilling targeted pharmaceutical needs for defense and veteran healthcare systems through the DLA's competitive procurement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 8/4/25 |